CHEK1 and neoplasm: Anti-PD-1, in combination with CHK1 inhibitors + HU, did not produce a potentiating effect, suggesting that this treatment (CHK1 inhibitor + HU) activates more prevalent mechanisms maintaining an immunosuppressive microenvironment and does not negatively affect immune responses, triggering a strong anti-tumor immune response [77].